Table 1.
Baseline characteristics and previous treatment history (n=22)
| Variables | n (%) or median (range) |
|---|---|
| Age, years | 30 (16–57) |
| Sex | |
| Male | 15 (68.2) |
| Female | 7 (31.8) |
| ECOG performance | |
| PS 0–1 | 10 (45.5) |
| PS 2–4 | 12 (54.5) |
| B-symptoms | |
| No | 7 (31.8) |
| Yes | 15 (68.2) |
| Extranodal involvement | |
| 0–1 | 14 (63.6) |
| 2 or more | 8 (36.4) |
| LDH elevated | |
| No | 15 (68.3) |
| Yes | 7 (31.8) |
| Stage | |
| I–II | 1 (4.5) |
| III–IV | 21 (95.5) |
| Pathology | |
| NSHL | 12 (54.5) |
| MCHL | 8 (36.4) |
| LRHL | 1 (4.5) |
| CHL, unspecified | 1 (4.5) |
| Nationality | |
| China | 14 (63.6) |
| South Korea | 6 (27.3) |
| Hong Kong | 2 (9.1) |
| Disease status | |
| Primary refractory disease | 12 (54.5) |
| Relapsed disease | 10 (45.5) |
| Previous chemotherapy lines | |
| 1–2 | 2 (9.1) |
| 3 or more | 20 (90.9) |
| Previous HSCT | |
| No | 5 (22.7) |
| Yes (auto and/or allo) | 17 (77.3) |
| Years between initial Dx and brentuximab | 3.4 (1.2–16.6) |
| Cycles of brentuximab | 5 (1–18) |
Abbreviations: CHL, classical Hodgkin lymphoma; Dx, diagnosis; ECOG, Eastern Cooperative Oncology Group; HSCT, hematopoietic stem cell transplantation; LDH, lactic dehydrogenase; LRHL, lymphocyte-rich Hodgkin lymphoma; MCHL, mixed-cellularity Hodgkin lymphoma; NSHL, nodular sclerosis Hodgkin lymphoma; PS, performance status.